전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,045 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleBiogenPhase 2

rituximab (IDEC-C2B8, IDEC-C2B8 (rituximab))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase2#monoclonal-antibody#Biogen
Trials 1Status Discontinued
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 + nivolumab)

Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#HeadandNeckCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleIkena OncologyPhase 1

nivolumab (Opdivo, IK-175 and nivolumab)

Urothelial Carcinoma; Urothelial Carcinoma Bladder · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase1#monoclonal-antibody#UrothelialCarcinomaBladder+1
Trials 1Status Active
ADCLimited DatastaleIksuda Therapeutics Ltd.Phase 1

IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody (IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody)

Colorectal Cancer; Gastro Esophageal Junctional Cancer · Colorectal Cancer

#ColorectalCancer#ADC#Phase1#antibody-drug-conjugate#GastroEsophagealJunctionalCancer+1
Trials 1Status Recruiting
CGTLimited DatastaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleSecond Affiliated Hospital, Sch…Approved

IL-17A/F mAb + NAFL (IL-17A/F mAb + NAFL)

Hidradenitis Suppurativa (HS) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Approved#monoclonal-antibody#Second
Trials 1Status Recruiting
AntibodyLimited DatastaleGregory DanielsPhase 2

nivolumab (Opdivo, IL-2 and Nivolumab)

Melanoma Stage Iv; Renal Cell Carcinoma, Metastatic · Melanoma Stage Iv

#MelanomaStageIv#Antibody#Phase2#monoclonal-antibody#RenalCellCarcinoma+2
Trials 1Status Discontinued
CGTLimited DatastaleMing YangPhase 1

IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody (IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody)

Recurrent Malignant Glioma · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

IL3 CAR T-cells (IL3 CAR T-cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 1

IM21 CAR-T cells (IM21 CAR-T cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

INDUCTION CTx (TPF, INDUCTION CTx, INDUCTION CTx(TPF)+(RT+CETUXIMAB))

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of Colorado, DenverPhase 1

IPI-926 and Cetuximab (IPI-926 and Cetuximab)

Recurrent Head and Neck Cancer · Recurrent Head and Neck Cancer

#RecurrentHeadandNeckCancer#Antibody#Phase1#monoclonal-antibody#University
Trials 1Status Active
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPreclinical

nivolumab (Opdivo, Immuno-oncology-based therapy, excluding nivolumab-based regimens, Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy)

Non-small Cell Lung Cancer (NSCLC) · Non-small Cell Lung Cancer (NSCLC)

#Non-smallCellLungCancerNSCLC#Antibody#Preclinical#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 3

Imprime PGG + cetuximab (Imprime PGG + cetuximab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#monoclonal-antibody#Eli
Trials 1Status Discontinued
AntibodyLimited DatastaleVanda PharmaceuticalsPhase 2

Imsidolimab (Imsidolimab)

Ichthyosis · Ichthyosis

#Ichthyosis#Antibody#Phase2#monoclonal-antibody#Vanda
Trials 1Status Discontinued
CGTLimited DatastaleLiping DouPhase 1

In vivo BCMA/GPRC5D Tandem Dual CAR-T cell (In vivo BCMA/GPRC5D Tandem Dual CAR-T cell)

Plasma Cell Neoplasms · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Induction dose of (Induction dose of, Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin)

Hepatitis C, Chronic · Hepatitis C, Chronic

#HepatitisCChronic#Antibody#Phase3#monoclonal-antibody#HepatitisC+2
Trials 1Status Active

68 / 103 pages

← PreviousNext →